Zostavax

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

InfluenzaKidney TransplantHerpes ZosterChickenpox

1053 competitors in Influenza

#DrugCompanyPhaseTrials

1

Zostavax

Merck & Co.

Approved

12

Fluzone

GSK

Preclinical

373

Crestor

AstraZeneca

Preclinical

14

Avigan

AAppili Therapeutics Inc.

Preclinical

65

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

306

COMIRNATY

Pfizer

Preclinical

17

Antihistamine

Arrowhead Pharmaceuticals

Preclinical

18

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

149

Fluvirin

Novartis

Preclinical

310

MF-59

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

1Show 12 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Immunogenicity6 trials

Safety and Immunogenicity of a Zoster Vaccine in SLE

Completed·TTuen Mun Hospital·Phase 4·NCT02477150·90 enrolled

Immunogenicity and Safety of a 1-dose Regimen of a Zoster Vaccine Versus Different 2-dose Regimens in Participants ≥ 70 Years of Age. (V211-043)

Completed·Merck & Co.·Phase 3·NCT00561080·759 enrolled

Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over

Completed·SSK Chemicals Co., Ltd.·Phase 3·NCT03120364·824 enrolled

Show 3 more trials

Immunogenicity and Safety of Two Lots of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over

Completed·SSK Chemicals Co., Ltd.·Phase 2/3·NCT03116594·675 enrolled

Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older

Terminated·UUniversity of South Florida·N/A·NCT02960399·2 enrolled

Immunogenicity and Safety Study of ZOSTAVAX Administered by Intramuscular or Subcutaneous Route to Participants Aged From 50 Years Old (V211-045)

Completed·Merck & Co.·Phase 3·NCT01391546·354 enrolled

Vaccine3 trials

Optimal Timing of Zoster Vaccine After Zoster Illness

Completed·SSeoul National University Hospital·N/A·NCT02704572·60 enrolled

Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00851786·395 enrolled

Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly

Completed·EEmory University·N/A·NCT01331161·77 enrolled

Herpes Zoster2 trials

Herpes Zoster Vaccine for Bone Marrow Transplant Donors

Completed·UUniversity of Sydney·Phase 2·NCT01573182·8 enrolled

Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds

Completed·UUniversity of Colorado, Denver·Phase 1·NCT02114333·160 enrolled

Varicella Zoster2 trials

Prevention of Varicella Zoster Virus (VZV)-Reactivation in HIV-positive Individuals Enrolled in a Prospective Immunogenicity and Safety Trial of VZV Vaccine: PROVE-IT-Study

Withdrawn·UUniversity of Zurich·Phase 1/2·NCT01213810

T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020

Completed·SStanford University·Phase 4·NCT01911065·54 enrolled

Hematopoietic Stem Cell Transplantation2 trials

Optimal Timing of Zoster Vaccine After Hematopoietic Stem Cell Transplantation

Completed·SSeoul National University Hospital·N/A·NCT03192319·86 enrolled

VZV Vaccine for Hematopoietic Stem Cell Transplantation

Completed·TThe University of Hong Kong·Phase 2/3·NCT02329457·100 enrolled

9 more indications

Effectiveness1 trial

ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)

Completed·Merck & Co.··NCT01600079·1,505,647 enrolled

Chickenpox1 trial

A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concomitantly With Another Vaccine (V211-011)

Completed·Merck & Co.·Phase 3·NCT00231816·763 enrolled

Kidney Transplant1 trial

Safety and Immunogenicity of Zostavax Vaccine in Patients Undergoing Living Donor Kidney Transplantation

Completed·UUniversity of Alberta·Phase 4·NCT00940940·4 enrolled

Adult1 trial

Safety Study of NBP608 in Healthy Adult Volunteers

Completed·SSK Chemicals Co., Ltd.·Phase 1·NCT03121638·150 enrolled

Chemotherapy1 trial

ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors

Unknown status·—·Phase 4·NCT02444936·22 enrolled

Vaccine Response1 trial

Zoster Vaccine Response in the Frail Elderly

Completed·MMcMaster University··NCT01328548·241 enrolled

Immune Response1 trial

Placebo Controlled Evaluation of the Cell Mediated Immune Response of Cirrhotic Subjects to Zostavax™

Completed·TTulane University·Phase 4·NCT02958345·28 enrolled

Influenza1 trial

Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)

Completed·Merck & Co.·Phase 3·NCT02519855·882 enrolled

Unspecified2 trials

Zostavax® at Minimum Release Specification Approaching Expiry (V211-044)

Completed·Merck & Co.·Phase 4·NCT00681031·96 enrolled

Persistence of Protection by Shingrix

Completed·UUniversity of Colorado, Denver·Phase 4·NCT04169009·105 enrolled

Details

Drug Info

Related News